

ASX ANNOUNCEMENT

14 June 2022

VIRTUS HEALTH LIMITED (ASX: VRT)

Virtus declares Special Dividend following increase in BGH Bidders' voting power and increase to BGH Offer consideration

Virtus Health Limited (ACN 129 643 492) (**Virtus**) is pleased to announce that it has declared a fully franked special dividend of 30 cents per Virtus share (**Special Dividend**).

The record date of the Special Dividend is 20 June 2022, and the payment date is 1 July 2022.

Virtus previously confirmed its intention to pay a special fully franked dividend of up to 30 cents per Virtus share if Oceania Equity Investments Pty Ltd as trustee of the Oceania Trust and A.C.N. 658 293 166 Pty Ltd (**BGH Bidders**) acquire voting power in Virtus of 90% or greater by 5pm on 14 June 2022. As at 9.00am on 14 June 2022, the BGH Bidders' voting power in Virtus was 90.38%.

Those Virtus shareholders that can capture the full benefit of the franking credits associated with the Special Dividend will receive additional value as a result of franking credits of up to 13 cents per Virtus share (depending on their tax status and specific circumstances).

Virtus also notes that:

- The BGH Bidders have agreed that they will not process acceptances under their takeover offer (**BGH Offer**) until at least two business days after the record date for the Special Dividend. This means that all Virtus shareholders who have accepted the BGH Offer will receive the Special Dividend, and eligible Virtus Shareholders may receive the benefit from the franking credits attached to the Special Dividend, subject to their marginal tax rate.
- On 13 June 2022, the BGH Bidders increased the consideration payable to Virtus shareholders under the BGH Offer by 0.5 cents per Virtus share to \$8.155 per Virtus share, less the amount of any dividend paid or declared. As a result of the increase in the consideration payable to Virtus Shareholders, the BGH Offer has been automatically extended so that it will now close on 27 June 2022, unless further extended.

Virtus encourages you to read the fifth supplementary target's statement which will be released today for further information about the BGH Offer.

This announcement is authorised by the Virtus Board.

-ENDS-

Further information:

Investor Enquiries:

Matt Prior
CFO, Virtus Health
+61 (0)498 003 973
matthew.prior@virtushealth.com.au

Media Enquiries:

Peter Brookes
Citadel Magnus
+61 (0)407 911 389
pbrookes@citadelmagnus.com

Virtus Health Limited (ASX:VRT) brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful ARS collaborations in the world. With 126 of the world's leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia, Ireland and Denmark, Singapore and UK.